The first evidence of an association between a polymorphism in the endocannabinoid-degrading enzyme FAAH (FAAH rs2295633) with attention deficit hyperactivity disorder

25Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Several single nucleotide polymorphisms (SNPs) of the fatty acid amide hydrolase (FAAH), the degrading enzyme of the endocannabinoids, have been shown to be associated with many neuropsychiatric disorders. Here, FAAH rs2295633 was studied in ADHD and case-control healthy children. There was a significant difference in the allele frequency (P = .04) and genotype distribution (P = .04) of the FAAH rs2295633 between ADHD cases and controls. The ADHD children appeared to have less of TT genotype (OR 0.396, 95% CI 0.178–0.884, p = .024) and T allele (OR 0.658, 95% CI 0.440–0.982, p = .04). To our best knowledge, this is the first statistical significant association between FAAH rs2295633 genotype and ADHD disorder. Larger sample sizes and functional studies are warranted to explore the clinical utility of FAAH genotyping as a possible marker for increased ADHD risk in children.

Cite

CITATION STYLE

APA

Ahmadalipour, A., Mehdizadeh Fanid, L., Zeinalzadeh, N., Alizadeh, M., Vaezi, H., Hassanpour Aydinlou, Z., & Noorazar, S. G. (2020). The first evidence of an association between a polymorphism in the endocannabinoid-degrading enzyme FAAH (FAAH rs2295633) with attention deficit hyperactivity disorder. Genomics, 112(2), 1330–1334. https://doi.org/10.1016/j.ygeno.2019.07.024

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free